Regulatory Insights from EMA CHMP Meeting Highlights

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal gel for Parkinson’s motor fluctuations, a once-weekly insulin for type 2 diabetes, and two biosimilars for cancer-related skeletal complications and chemotherapy-induced neutropenia.

Full CHMP recommendations also included a re-examination success for a Rett syndrome neurobehavioural treatment, later restricted to patients five years and older.

Re-Examination Flips Initial Refusal

A formal re-examination procedure reversed an earlier negative opinion for the Rett syndrome medicine after deeper review of its impact on repetitive movements, anxiety, and communication deficits. This outcome demonstrates how structured appeal pathways can refine indications when additional evidence is compelling.

Advanced Therapies Fall Short

Three applications received negative opinions, including an autologous TIL therapy for advanced melanoma, a treatment for transplant-associated thrombotic microangiopathy, and an allogeneic faecal microbiota product for acute graft-versus-host disease. The decisions reinforce the committee’s insistence that clinical benefit must clearly outweigh risk in high-stakes settings.

Extensions Broaden Patient Reach

Eleven existing medicines gained expanded indications, most notably lowering the minimum age for a modified vaccinia Ankara vaccine from 12 to 2 years for smallpox, mpox, and vaccinia protection. The committee also incorporated cardiovascular outcomes data for a tirzepatide product into its labelling despite declining a formal expanded claim.

Data Integrity Triggers Revocation

Safety and quality referrals under Article 31 led to the revocation of a medicine for severe granulomatosis with polyangiitis and microscopic polyangiitis after unresolved concerns about pivotal trial integrity. Similar scrutiny continues for a rifampicin oral suspension regarding potential excipient carcinogenicity observed in animal studies.

EMA CHMP Meeting Highlights Shape Future Access

These EMA CHMP Meeting Highlights send clear signals to developers about the level of evidence required for oncology, immunology, and rare-disease programmes in Europe. By approving select innovations, narrowing labels, and revoking approvals where standards slipped, the committee directly influences which therapies reach clinicians and patients across the EU.

Summary of Key CHMP Decisions (22-25 June 2026)

Category	Product Name	Active Substance / Type	Key Indication / Change	Notes / Applicant
New Medicine	Aujemflu	Inactivated influenza vaccine	Prophylaxis of influenza in adults ≥50 years	Seqirus Netherlands BV
New Medicine	Hopledo	Levodopa / carbidopa	Parkinson’s disease with motor fluctuations in adults	Zambon S.p.A.
New Medicine	Onswik	Insulin efsitora alfa	Treatment of type 2 diabetes mellitus in adults	Eli Lilly Nederland B.V.
Biosimilar	Denosumab Ascend	Denosumab (biosimilar)	Prevention of skeletal-related events in advanced cancer; giant cell tumour of bone	Ascend GmbH
Biosimilar	Nylaspeg	Pegfilgrastim (biosimilar)	Reduction of neutropenia and febrile neutropenia due to chemotherapy	Qilu Pharma Spain S.L.
Re-examination	Daybu	Trofinetide	Neurobehavioural symptoms of Rett syndrome (adults & paediatrics ≥5 years)	Acadia Pharmaceuticals (Netherlands) B.V. (Orphan)
Negative Opinion	Tacquell	Autologous TIL therapy	Advanced melanoma	Netherlands Cancer Institute
Negative Opinion	Yartemlea	Narsoplimab	HSCT-associated thrombotic microangiopathy	Omeros Ireland Limited (Orphan)
Negative Opinion	Xervyteg	Allogeneic faecal microbiota	Acute graft-versus-host disease (aGvHD)	MaaT PHARMA
Extension	Imvanex	Modified vaccinia Ankara vaccine	Lowered minimum age to ≥2 years (smallpox, mpox, vaccinia)	Bavarian Nordic A/S
Extension (other)	Datroway, Jaypirca, Leqvio, Menquadfi, Opzelura, Rezolsta, Rinvoq, Stelara, Symtuza, Tecvayli	Various	Various expanded indications	Multiple holders
Referral – Revocation	Tavneos	Avacopan	Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)	Revoked due to data integrity concerns
Referral – Review	Rifadin	Rifampicin oral suspension	Review due to excipient (DEA) carcinogenicity concerns	Ongoing
Other Update	Mounjaro	Tirzepatide	CV outcomes data added to labelling (no formal new indication)	Eli Lilly